Aegerion Pharmaceuticals , Nasdaq: AEGR
Developing a drug for an orphan disease that produces fatal levels of cholesterol.
Industry: Health Care
First Day Return: +10.5%
| IPO Data | |
|---|---|
| IPO Date | 10/21/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $48 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Bridgewater, NJ, United States |
| Founded | 2005 |
| Employees at IPO | 9 |
| Website www.aegerion.com | |
Aegerion Pharmaceuticals (AEGR) Performance
